Evidence map›Paper›PMID 37663576›Full record

ArticleJournal of virus eradication2023

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.

Caroline Schwarz, Raphael Schubert, Michael Schwarz, Angelika Schütz, Anika Jenke, David Bauer, Benjamin Steinwender, Enisa Gutic, Thomas Reiberger, Hans Haltmayer and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of virus eradication, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. A systematic PCR record-based re-call of HCV-RNA-positive people enables re-linkage to care and HCV elimination in Austria - The ELIMINATE project.Liver international : official journal of the International Association for the Study of the Liver · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Caroline SchwarzKlinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Raphael SchubertSuchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria.
Michael SchwarzKlinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Angelika SchützSuchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria.
Anika JenkeSuchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria.
David BauerKlinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Benjamin SteinwenderSuchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria.
Enisa GuticKlinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Thomas ReibergerMedical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria.
Hans HaltmayerSuchthilfe Wien gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria.
Michael GschwantlerKlinik Ottakring, Department of Internal Medicine IV, Vienna, Austria.
Austrian Breast & Colorectal Cancer Study Group · ATSigmund Freud Privatuniversität Wien · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). Methods: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed. Results: 4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred. Conclusion: Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs.

Indexed as

Directly observed therapyEliminationHCVPeople who inject drugsPWIDsScreening

Identifiers

PMID37663576
PMCPMC10474458
OpenAlexW4385326374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.